A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation
Clinical trial NCT04691648 · COMPLETED
Trial details
- NCT number
- NCT04691648
- Sponsor
- Astellas Pharma Korea, Inc.
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-06-17
- Primary completion
- 2025-05-04
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.